MedTrace Logo

A Penicillin Allergy Delabeling Inhospital Model Hospitalized Patients

NCT07194824 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2026-01-13

No results posted yet for this study

Summary

Design, implementation and analysis of an allergy assessment and management model beta-lactams in hospitalized patients

Conditions

  • Allergy Drug
  • Allergy Penicillin

Interventions

OTHER

Pragmatic allergy management according to risk stratification

Intervention based on allergy risk stratification. Tipus A) Patients in this group can undergo direct delabeling without the need for exposure, with this being documented in the EMR. If the patient refuses, an exposure to penicillin and/or cephalosporin will be performed. Once completed, de-labeling can proceed without the need for re-exposure. Tipus B) Indication for use of a penicillin: Oral exposure to 250 mg of amoxicillin. \- Indication for cephalosporin : administration of a cephalosporin that exhibits the lowest level of cross-reactivity with penicillin. Re-exposure to penicillin/ cephalosporin or both is performed at least 2 weeks after the first tolerated exposure. De-labeling is performed when tolerance to re-exposure is verified. Tipus C) These high-risk patients are managed following the protocol for the treatment of patients with beta-lactam allergy, referring them to allergy consultation for further specific test.

Sponsors & Collaborators

  • Althaia Xarxa Assistencial Universitària de Manresa

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-04
Primary Completion
2025-05-23
Completion
2025-05-25

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07194824 on ClinicalTrials.gov